Can a patient with latent autoimmune diabetes in adults (LADA) be treated with Jardiance (empagliflozin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can a Patient with LADA Take Jardiance?

No, Jardiance (empagliflozin) should not be used in patients with LADA because it is FDA-approved only for type 2 diabetes and heart failure, and LADA is formally classified as type 1 diabetes—a population in which SGLT2 inhibitors carry an increased risk of life-threatening diabetic ketoacidosis. 1

Why Jardiance Is Contraindicated in LADA

FDA Labeling Explicitly Excludes Type 1 Diabetes

  • Jardiance is not recommended in patients with type 1 diabetes mellitus because it may increase the risk of diabetic ketoacidosis 1.
  • LADA, despite its phenotypic overlap with type 2 diabetes at presentation, is formally classified as type 1 diabetes due to the presence of islet autoantibodies (particularly GAD antibodies) and progressive autoimmune destruction of pancreatic beta cells 2, 3, 4.
  • The FDA label states that Jardiance is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and explicitly notes the limitation: "JARDIANCE is not recommended in patients with type 1 diabetes mellitus" 1.

Elevated Risk of Diabetic Ketoacidosis (DKA)

  • SGLT2 inhibitors, including empagliflozin, carry a serious risk of ketoacidosis—including euglycemic DKA (ketoacidosis with blood glucose <250 mg/dL)—which can be life-threatening 5, 6, 1.
  • The ADA 2025 guideline notes that "the use of SGLT inhibitors increases the susceptibility to diabetic ketoacidosis, particularly when other risk factors or situations occur (including, but not limited to, insulin pump malfunctions, significant reduction in insulin doses, and nutritional intake plans with prolonged periods of fasting or carbohydrate restriction)" 5.
  • In placebo-controlled trials of patients with type 1 diabetes, the risk of ketoacidosis was increased in patients who received SGLT2 inhibitors compared to placebo 1.
  • LADA patients have ongoing autoimmune beta-cell destruction and often require insulin therapy within a few years of diagnosis 2, 4; this progressive insulin deficiency heightens DKA risk when SGLT2 inhibitors are used.

Clinical Reasoning: Why LADA Is Not Type 2 Diabetes

Autoimmune Pathophysiology

  • LADA is characterized by positive islet autoantibodies (especially GAD >250 IU/mL), progressive beta-cell failure, and eventual insulin dependence—features that align it with type 1 diabetes 3, 4, 7.
  • Although LADA patients may initially present with insulin resistance and overweight (mimicking type 2 diabetes), the decline in beta-cell function progresses much faster in LADA than in type 2 diabetes due to the ongoing autoimmune assault 2.
  • A recent case report emphasizes that proper diagnosis of LADA (via autoantibody testing) prompts appropriate pharmacotherapy—specifically, discontinuation of oral agents like metformin and initiation of insulin 7.

Misdiagnosis Is Common but Dangerous

  • LADA is frequently misdiagnosed as type 2 diabetes because patients are initially insulin-independent and may have metabolic features (e.g., overweight, insulin resistance) that overlap with type 2 diabetes 3, 4, 8.
  • However, using type 2 diabetes therapies (including SGLT2 inhibitors) in LADA can accelerate beta-cell loss and increase the risk of acute metabolic decompensation 4, 7.
  • The prevalence of LADA is approximately 7–10% of all diabetes cases, with higher rates in North America (15%) 8; thus, screening for autoantibodies (GAD, IA-2) is crucial when clinical features suggest LADA (e.g., lean body habitus, rapid glycemic deterioration, low-normal C-peptide) 7, 9.

What Should Be Done Instead

Insulin Therapy Is the Cornerstone

  • LADA patients should be treated with insulin to preserve residual beta-cell function and prevent metabolic decompensation 2, 4, 7.
  • A basal-bolus insulin regimen is appropriate once LADA is diagnosed, even if the patient is not yet insulin-dependent 7.

Avoid Treatments That May Accelerate Beta-Cell Loss

  • Sulfonylureas should be avoided in LADA because they may accelerate beta-cell exhaustion 4.
  • SGLT2 inhibitors (including Jardiance) should not be used due to the increased DKA risk and lack of FDA approval in type 1 diabetes 1.

Consider Metformin Cautiously

  • Metformin may be used in LADA patients with significant insulin resistance, but it should not delay insulin initiation 4.
  • If autoantibodies are positive and C-peptide is low-normal, metformin should be discontinued and insulin started promptly 7.

Key Pitfalls to Avoid

  • Do not rely solely on C-peptide to rule out LADA: A low-normal C-peptide (e.g., 1.3 ng/mL) in the context of rapid glycemic deterioration should prompt autoantibody testing 7.
  • Do not assume LADA is type 2 diabetes based on initial presentation: The presence of overweight or insulin resistance does not exclude LADA 3, 4.
  • Do not use SGLT2 inhibitors off-label in LADA: The cardiovascular and renal benefits of empagliflozin seen in type 2 diabetes trials 5, 6 do not apply to LADA, and the DKA risk is unacceptably high 1.

References

6
Guideline

Safety and Efficacy of Empagliflozin (Jardiance) in Adults with Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

When should empagliflozin (Jardiance) be started in an adult with type 2 diabetes?
In a 74-year-old male with latent autoimmune diabetes in adults (LADA), weight 67 kg, creatinine 1.25 mg/dL, eGFR 60 mL/min/1.73 m², on basal insulin glargine (Lantus) 18 U, insulin sensitivity factor 25, insulin‑to‑carbohydrate ratio 6, who has been NPO since midnight, received prednisolone 10 mg at 8 am and dexamethasone 10 mg at 2 pm, with blood glucose around 210‑220 mg/dL, what insulin dosing should be given now and for the planned evening meal at 6 pm?
What is the likely cause and recommended management for a 34‑year‑old woman with controlled type 2 diabetes mellitus on empagliflozin (Jardiance), metformin, and levothyroxine (Synthroid) who has had five days of swelling, pain, and redness of the labia and clitoris unresponsive to topical clobetasol?
In a 74-year-old man with latent autoimmune diabetes in adults (LADA), weight 67.6 kg, estimated glomerular filtration rate (eGFR) 60 mL/min, who took basal insulin glargine (Lantus) 18 units at 8 am and has an insulin‑to‑carbohydrate ratio (ICR) of 6 g per unit, with blood glucose 210 mg/dL at noon after being nil per os (NPO) with high‑dose correction and who received dexamethasone 10 mg at 2 pm and is now eating, should I increase his ICR or insulin sensitivity factor (ISF) for dinner?
In a patient with well‑controlled hemoglobin A1c who is taking empagliflozin (Jardiance) and now has a groin fungal infection (tinea cruris), should the empagliflozin be continued and what is the appropriate treatment for the rash?
What are the differential diagnoses for a sickle cell anemia patient with prior cholecystectomy and splenectomy who presents with fever of unknown origin, elevated lactate dehydrogenase, and elevated total bilirubin?
Is it appropriate to reduce clozapine dose from 300 mg to 200 mg without physician guidance?
Should lactate dehydrogenase (LDH) be ordered as part of the work‑up for a monoclonal gammopathy?
What are the grades of diastolic dysfunction, what do they signify clinically, and what are the common causes?
Which silicone‑based barrier cream (e.g., Cavilon Barrier Cream, dimethicone) should be used for a resident with perianal soreness, no diarrhea, and current twice‑daily zinc‑oxide ointment (Desitin) application to prevent sacral redness from wiping?
Which serum hormones should be measured on day 3 of the menstrual cycle and what are their normal reference ranges in a reproductive‑age woman?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.